The FDA rejected Summit’s ivonescimab on November 15, 2026, ruling that a PFS benefit in EGFR mutated NSCLC cannot stand in for a significant survival win.
Last updated: November 16, 2026
The FDA issued a complete response letter for ivonescimab in EGFR mutated NSCLC after TKI therapy, stating that substantial evidence of effectiveness is not established without a statistically significant overall survival improvement. Summit announced the decision Sunday, November 15, 2026.
This page covers the ivonescimab complete response letter, the HARMONi data behind it, the contrasting Imfinzi plus Padcev approval, ObesityWeek 2026 results, the weekend’s financing tape, and Friday’s notable closes.
What did the FDA say in the ivonescimab complete response letter?
The FDA told Summit Therapeutics that the ivonescimab biologics license application cannot be approved in its present form, because substantial evidence of effectiveness is not established in the absence of a statistically significant overall survival improvement. Summit disclosed the letter on Sunday, November 15.
The application covered ivonescimab, a PD-1 x VEGF bispecific antibody invented by Akeso, in combination with platinum containing chemotherapy for locally advanced or metastatic non small cell lung cancer (NSCLC) in patients previously treated with an EGFR tyrosine kinase inhibitor. According to Summit’s release, the agency said a progression free survival benefit without a statistically significant overall survival benefit does not support a positive benefit risk profile for approval. The company noted that no FDA approved regimen in this specific setting has demonstrated a statistically significant overall survival benefit, and that the primary overall survival analysis showed a positive trend that did not reach significance. The target action date was Saturday, November 14; Summit announced the letter the following morning.
Summit’s release names no resubmission plan, no new trial commitment for this indication, and no timeline. Co CEO Robert Duggan said the company is disappointed for patients and their families awaiting additional options, and that with five positive Phase III studies between Summit and Akeso the companies’ commitment to ivonescimab is unchanged.
What did the HARMONi trial actually show?
HARMONi met its progression free survival endpoint decisively and missed statistical significance on overall survival. That gap is the whole story of the rejection.
| HARMONi endpoint | Ivonescimab + chemo | Chemo control | Result |
|---|---|---|---|
| Progression free survival (primary) | Median 6.8 months | 4.4 months | HR 0.52 (per Summit’s August 2026 release) |
| Overall survival (primary analysis) | Median 16.8 months | 14.0 months | HR 0.79, p=0.057 (per Summit’s September 2026 8-K) |
| Overall survival (post hoc, longer follow up) | Consistent across regions | HR 0.76 in full, Asian and Western populations (per Summit’s November 15 release) | |
| Discontinuation from treatment related adverse events | 7.3% (16 patients) | 5.0% (11 patients) | Per November 15 release |
| Deaths from treatment related adverse events | 1.8% (4 patients) | 2.3% (5 patients) | Per November 15 release |
The p=0.057 figure is the hinge. A hazard ratio of 0.79 with a p value just above the 0.05 line is a survival signal most oncologists would call real and no statistician can call counted. The FDA chose the statistician’s answer.
What happens to Summit and the PD-1 x VEGF class now?
The near term answer runs through HARMONi-3, the first line Phase III in metastatic NSCLC with squamous and non squamous cohorts analyzed separately. Enrollment is complete, the squamous cohort’s progression free survival event threshold was expected in the fourth quarter of 2026 per Summit’s third quarter release, and a survival interim analysis is expected in the first half of 2027, per trade coverage of the program. After this letter, the overall survival numbers in HARMONi-3 carry the weight of the entire United States program.
The broader pipeline continues: HARMONi-7 in first line PD-L1 high NSCLC as monotherapy, HARMONi-GI3 in first line metastatic colorectal cancer, HARMONi-GU1 in urothelial cancer with enfortumab vedotin, and a Phase II in clear cell renal cell carcinoma, plus combination work with AstraZeneca and Daiichi Sankyo’s DATROWAY, Revolution Medicines’ RAS inhibitors, GSK and Arcus. Akeso reports more than 100,000 patients treated with ivonescimab globally including commercial use in China, where the drug was first approved in May 2024.
For the wider PD-1 x VEGF field, the letter sets the bar in plain terms: in the United States, a progression free survival win plus a survival trend is not an approval. Every bispecific sponsor designing a registrational program now has to power for overall survival or pick settings where a surrogate can stand alone. Summit closed Friday at $14.15, down 6.1% on the week’s final session before the decision; Monday is the first session that prices the letter.
Why did the FDA approve Imfinzi plus Padcev the same weekend?
Two days before the ivonescimab letter, the same agency approved AstraZeneca’s durvalumab (Imfinzi) with enfortumab vedotin-ejfv (Padcev) for muscle invasive bladder cancer, six weeks ahead of its goal date. The difference in the data is instructive.
Per the FDA’s November 13 approval notice, the VOLGA trial (NCT04960709) randomized 695 patients who were ineligible for or refused cisplatin based chemotherapy to neoadjuvant durvalumab plus enfortumab vedotin followed by radical cystectomy and adjuvant durvalumab, versus surgery alone. Event free survival, the primary endpoint, showed a hazard ratio of 0.51 (95% CI 0.38 to 0.67, p<0.0001), with median event free survival not reached versus 12.1 months. Overall survival, a secondary endpoint, was also counted: hazard ratio 0.58 (95% CI 0.40 to 0.83, p=0.0027). The review ran under Project Orbis.
| The weekend’s two decisions | Ivonescimab (Summit) | Imfinzi + Padcev (AstraZeneca) |
|---|---|---|
| Setting | EGFR mutated NSCLC after TKI | Muscle invasive bladder cancer, cisplatin ineligible |
| Primary endpoint | PFS, HR 0.52 | EFS, HR 0.51, p<0.0001 |
| Overall survival | HR 0.79, p=0.057 (not significant) | HR 0.58, p=0.0027 (significant) |
| Outcome | Complete response letter | Approved six weeks early |
Identical hazard ratios on the primary endpoint. The file with the counted survival statistic was approved ahead of schedule; the file without one was refused. That is as clean a statement of current FDA practice as the industry will get.
What data moved at ObesityWeek 2026?
ObesityWeek opened Saturday in Washington DC and the weekend’s releases pushed the field well beyond the scale: sleep apnea, knee osteoarthritis, adolescents, children, and a first treatment for a bariatric surgery complication.
| Program | Readout | Key figure (company reported) |
|---|---|---|
| Lilly EloraTZP (eloralintide + tirzepatide), Phase 2 | Adults with obesity or overweight and type 2 diabetes, 48 weeks | Weight loss up to an average 54.1 lbs (23.3%); up to 60% no longer met BMI criteria for obesity; A1C down up to an average 2.9 points |
| Lilly retatrutide, TRIUMPH-1 and TRIUMPH-2, Phase 3 | Obstructive sleep apnea, 80 weeks | AHI reduced up to an average 36.1 events per hour (60.6%); 28.4 (48.1%) with type 2 diabetes |
| Lilly retatrutide, TRIUMPH-1 and TRIUMPH-4, Phase 3 | Knee osteoarthritis pain | WOMAC pain reduced up to an average 4.5 points (75.8%) |
| Lilly Zepbound, SURMOUNT-ADOLESCENTS, Phase 3 | Ages 12 to under 18, 72 weeks | BMI reduced an average 21.4%; more than half no longer met obesity criteria |
| Novo Nordisk semaglutide, STEP Young, Phase 3 | 165 children aged 6 to under 12, 68 weeks | 40.4% no longer classified as having obesity versus none on placebo; more than 85% had severe obesity at baseline |
| Amylyx avexitide, LUCIDITY, Phase 3 | Post bariatric hypoglycemia, n=78, 16 weeks | Composite hypoglycemic events reduced 55% (p=0.0000034); NDA planned by year end |
| Viking VK2735 subcutaneous, VENTURE Phase 2 analysis | BMI category shift at 13 weeks | 74% improved at least one BMI category versus 15% on placebo |
Amylyx’s LUCIDITY result stands out commercially: post bariatric hypoglycemia has no approved therapy, the trial met its primary endpoint and every multiplicity controlled secondary, there were no treatment related serious adverse events, and the company says it is moving with urgency toward a New Drug Application by year end with a potential 2027 launch. Novo’s STEP Young data, under the trial product estimand, moved two of five children below the obesity threshold within about a year, in a population where more than 85% started with severe obesity, with no new safety concerns on growth or puberty. Rhythm Pharmaceuticals, whose counted BMI curves we flagged Friday as the week’s test, had issued no new release through Sunday night; its newest posted release is dated November 4.
How did the financing window hold up on Friday?
Friday produced the cleanest version yet of the pattern we have tracked for two weeks: data in the morning, a raise within the hour, and a market that pays the pre data end of the curve best.
Rezolute announced positive preliminary topline results from its Phase 3 upLIFT study of ersodetug in tumor hyperinsulinism at 6:18 am Eastern on Friday: 13 of 16 participants met the response criterion of at least a 50% reduction in intravenous glucose infusion rate, with 12 stopping intravenous glucose entirely, against a prespecified significance threshold of a 56% response rate, per the company’s release as carried by wire aggregators. One minute later, at 6:19 am, Rezolute priced an underwritten offering of roughly $100 million: 22,040,976 shares at $3.87 plus pre funded warrants, led by Frazier Life Sciences, closing on or about November 16. The offering priced exactly at Thursday’s close, and the stock finished Friday at $3.655, 5.6% below the print. Full statistical results are expected by mid December, with FDA discussions in the first quarter of 2027.
Windward Bio, the Basel antibody company that priced its Nasdaq IPO Thursday night at $17.00 with Sanofi anchoring a concurrent $50 million placement, closed its first session Friday at $28.50, 67.6% above the offer, after trading as high as $33.99 intraday. Vir Biotechnology, which priced $150 million of stock at $10.00 Thursday night within 96 hours of its hepatitis B rally, closed its first post pricing session at $9.96, below the offering price. Surrozen closed at $31.61 against its $31.67 offering, and InspireMD’s $37.5 million raise, announced 14 minutes after its CGuard Prime approval last week, closes Monday. All percentage calculations here are ours from exchange settled closes.
Which stocks moved on Friday, November 13?
| Ticker | Friday close | Move | Context |
|---|---|---|---|
| WWB | $28.50 | +67.6% vs $17.00 offer | First session; pre data respiratory biologics; close expected Monday |
| VIR | $9.96 | −17.8% | First reaction to the $150M offering priced at $10.00; closed below the print |
| SMMT | $14.15 | −6.1% | Final session before the weekend FDA decision; Monday prices the letter |
| RZLT | $3.655 | −5.6% | Phase 3 win and $100M raise announced one minute apart pre market |
| ENGN | $2.41 | +5.7% | Second session of the bladder cancer durability rally |
| RYTM | $115.02 | +4.7% | Into ObesityWeek; no new company release through Sunday |
Index context: XBI closed at 150.55, down 0.4%, and SPY at 754.37, down 0.4%. Moves are our arithmetic from Thursday’s settled closes.
What else crossed the weekend wire?
Blackstone Life Sciences will put up to $1.5 billion into Pfizer’s obesity program, announced the prior Wednesday and worth catching up on: the funding supports as many as 10 Phase 3 trials of berobenatide, the once monthly injectable Pfizer acquired with Metsera, with contributions phased through 2028 and milestones owed only on approval as a once monthly single agent plus sales goals, per the companies via BioPharma Dive. uniQure’s gene therapy for Huntington’s disease, ifezuntirgene inilparvovec (AMT-130), was accepted by the FDA with priority review on November 2, with a decision date of May 1, 2027, per multiple trade reports of the company’s announcement. Zai Lab said KarXT and VYVGART Hytrulo were added to China’s 2026 National Reimbursement Drug List for the first time. China’s comment period on the draft export control catalogue covering biotech platform technologies closed Sunday, November 15; the final catalogue is now the watch item. Alpha Tau reported interim United States data for Alpha DaRT in recurrent glioblastoma, a 100% objective response rate in six evaluable patients with median survival not reached, ahead of a Monday call; the denominator is six. Helus Pharma presents Phase 3 APPROACH topline results for HLP003 in major depressive disorder on Monday. BioXcel’s Igalmi at home supplemental application had a Saturday, November 14 target action date; as of Sunday night we found no announcement from the company in either direction, a silence we note with that scope. AstraZeneca’s approval, Lilly’s presentations and the FDA notice above round out a weekend in which the agency, not the market, was the main character.
Frequently asked questions
What is ivonescimab?
Ivonescimab is a bispecific antibody that blocks both PD-1 and VEGF in one molecule. It was invented by Akeso, is approved and marketed in China, and is licensed to Summit Therapeutics in the United States and other territories, where it remains investigational.
Why did the FDA reject ivonescimab?
Per Summit’s November 15, 2026 release, the FDA said substantial evidence of effectiveness was not established because the HARMONi trial’s overall survival improvement was not statistically significant, and a progression free survival benefit alone does not support a positive benefit risk profile in this setting.
Did ivonescimab fail the HARMONi trial?
No. HARMONi met its progression free survival primary endpoint with a hazard ratio of 0.52. Overall survival showed a hazard ratio of 0.79 with p=0.057, a positive trend that fell short of statistical significance, which is what the FDA’s letter turned on.
Is a complete response letter the same as a permanent rejection?
No. A complete response letter means the application cannot be approved in its present form. Sponsors can resubmit with new data or analyses. Summit has not announced a resubmission plan for this indication.
What is HARMONi-3 and when does it read out?
HARMONi-3 is Summit’s Phase III trial of ivonescimab in first line metastatic NSCLC, with squamous and non squamous cohorts analyzed separately. Enrollment is complete; the squamous cohort’s progression free survival analysis threshold was expected in the fourth quarter of 2026, with a survival interim expected in the first half of 2027 per trade coverage.
What does the ivonescimab decision mean for other PD-1 x VEGF drugs?
It signals that United States approval in settings like this requires a statistically significant overall survival benefit, not just a progression free survival win. Sponsors of competing bispecifics will need survival powered registrational trials or settings where surrogates are accepted.
What did the FDA approve for muscle invasive bladder cancer?
On November 13, 2026, the FDA approved durvalumab (Imfinzi) with enfortumab vedotin-ejfv (Padcev) as neoadjuvant treatment, followed by adjuvant durvalumab after surgery, for adults with muscle invasive bladder cancer who are ineligible for or refuse cisplatin based chemotherapy, based on the VOLGA trial.
What did the VOLGA trial show?
Per the FDA notice, event free survival had a hazard ratio of 0.51 (p<0.0001) with the median not reached versus 12.1 months for surgery alone, and overall survival had a hazard ratio of 0.58 (p=0.0027). The approval came six weeks ahead of the goal date.
What did Novo Nordisk’s STEP Young trial show in children?
In 165 children aged 6 to under 12 with obesity, 40.4% of those on weekly semaglutide plus lifestyle changes were no longer classified as having obesity at week 68, versus none on placebo, under the trial product estimand. Novo reported no new safety concerns, including on growth and puberty.
What is avexitide and why does LUCIDITY matter?
Avexitide is Amylyx’s GLP-1 receptor antagonist for post bariatric hypoglycemia, a complication of weight loss surgery with no approved therapy. The Phase 3 LUCIDITY trial cut composite hypoglycemic events by 55% versus placebo (p=0.0000034), and Amylyx plans a New Drug Application by year end 2026.
How did the Windward Bio IPO perform?
Windward Bio priced 10,294,117 shares at $17.00 on November 12 with a concurrent $50 million Sanofi private placement, about $225 million expected gross in total, and closed its first Nasdaq session on November 13 at $28.50, 67.6% above the offer price by our arithmetic.
Did Rezolute’s upLIFT study succeed?
Per the company, yes on the preliminary count: 13 of 16 participants with tumor hyperinsulinism met the response criterion against a 56% significance threshold, with 12 stopping intravenous glucose entirely. Completed study results with full statistics are expected by mid December 2026.
What happened with BioXcel’s Igalmi decision?
The target action date for the at home supplemental application was Saturday, November 14, 2026. As of Sunday night, November 15, we found no company announcement of an approval, rejection, or extension; that check covered the company’s wire feeds and dated news indexes.
When does China’s biotech export control rule take effect?
There is no final rule yet. The comment period on the draft catalogue, which would ban foreign acquisition of certain cell and gene therapy and siRNA platform technologies while leaving out licensing untouched, closed November 15, 2026. The final catalogue and its scope are the next watch item.
Sources
- Summit Therapeutics press release, “Summit Therapeutics Provides Update Regarding Ivonescimab Biologics License Application,” November 15, 2026 (primary)
- FDA approval notice, “FDA approves durvalumab with enfortumab vedotin-ejfv for muscle invasive bladder cancer,” November 13, 2026 (primary)
- Amylyx Pharmaceuticals press release, Phase 3 LUCIDITY results, November 14, 2026 (primary)
- Novo Nordisk press release, STEP Young Phase 3 results (primary)
- Eli Lilly press release, ObesityWeek 2026 presentations, November 14, 2026 (primary, via wire carry)
- Viking Therapeutics press release, VK2735 VENTURE analysis at ObesityWeek, November 15, 2026 (primary, via wire carry)
- Rezolute press releases, upLIFT topline and offering pricing, November 13, 2026 (via wire carries; upLIFT figures attributed)
- Summit Therapeutics August 2026 HARMONi release and September 2026 8-K (PFS and OS figures, as previously disclosed)
- BioPharma Dive, Blackstone and Pfizer obesity funding agreement, November 12, 2026 (deal terms attributed to the companies)
- STAT News and trade coverage of the ivonescimab decision, November 15, 2026 (corroboration)
- Robinhood exchange settled closes, November 13, 2026 (all price moves our arithmetic)
Related coverage
- FDA rejects ivonescimab over missing overall survival win: the decision explained
- What a complete response letter is and what happens after one
- The Imfinzi plus Padcev VOLGA approval in cisplatin ineligible bladder cancer
- How Project Orbis shares FDA cancer drug reviews across regulators
- enGene’s 27% move on bladder cancer durability data


